Akeso Future Growth

Future criteria checks 6/6

Akeso is forecast to grow earnings and revenue by 55.1% and 32.8% per annum respectively. EPS is expected to grow by 54.3% per annum. Return on equity is forecast to be 22.4% in 3 years.

Key information

55.1%

Earnings growth rate

54.3%

EPS growth rate

Biotechs earnings growth	38.9%
Revenue growth rate	32.8%
Future return on equity	22.4%
Analyst coverage	Good
Last updated	01 Sep 2024

Recent future growth updates

Akeso, Inc. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Aug 30

Results: Akeso, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Mar 20

The Akeso, Inc. (HKG:9926) Half-Yearly Results Are Out And Analysts Have Published New Forecasts

Aug 31

Recent updates

Akeso, Inc. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Aug 30

Akeso, Inc.'s (HKG:9926) CEO Compensation Is Looking A Bit Stretched At The Moment

Jun 24

Little Excitement Around Akeso, Inc.'s (HKG:9926) Revenues As Shares Take 25% Pounding

Jun 19

Results: Akeso, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Mar 20

Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price

Dec 28

An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 34% Undervalued

Nov 16

Is Akeso (HKG:9926) Using Too Much Debt?

Oct 02

The Akeso, Inc. (HKG:9926) Half-Yearly Results Are Out And Analysts Have Published New Forecasts

Aug 31

Is Akeso, Inc. (HKG:9926) Trading At A 40% Discount?

Jun 26

There's Reason For Concern Over Akeso, Inc.'s (HKG:9926) Price

May 22

Health Check: How Prudently Does Akeso (HKG:9926) Use Debt?

Apr 11

Growth Investors: Industry Analysts Just Upgraded Their Akeso, Inc. (HKG:9926) Revenue Forecasts By 18%

Mar 21

An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 49% Undervalued

Mar 02

Akeso, Inc.'s (HKG:9926) Intrinsic Value Is Potentially 95% Above Its Share Price

Nov 01

Time To Worry? Analysts Are Downgrading Their Akeso, Inc. (HKG:9926) Outlook

Aug 28

Earnings and Revenue Growth Forecasts

SEHK:9926 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	6,077	1,161	1,154	1,497	23
12/31/2025	4,053	186	-18	324	23
12/31/2024	2,615	-356	-728	-301	20
6/30/2024	1,874	-735	-1,629	-750	N/A
3/31/2024	3,200	646	-21	859	N/A
12/31/2023	4,526	2,028	1,588	2,468	N/A
9/30/2023	4,439	2,008	1,459	2,340	N/A
6/30/2023	4,351	1,987	1,330	2,212	N/A
3/31/2023	2,595	409	-356	486	N/A
12/31/2022	838	-1,168	-2,043	-1,240	N/A
9/30/2022	549	-1,224	-1,997	-1,238	N/A
6/30/2022	260	-1,280	-1,952	-1,235	N/A
3/31/2022	243	-1,178	-1,835	-1,118	N/A
12/31/2021	226	-1,075	-1,717	-1,001	N/A
9/30/2021	177	-1,002	-1,525	-882	N/A
6/30/2021	129	-929	-1,333	-762	N/A
3/31/2021	64	-983	-1,200	-690	N/A
12/31/2020	N/A	-1,036	-1,066	-618	N/A
9/30/2020	35	-870	-814	-443	N/A
6/30/2020	71	-703	-562	-267	N/A
3/31/2020	71	-492	-459	-243	N/A
12/31/2019	71	-282	-356	-220	N/A
12/31/2018	3	-142	-198	-123	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 9926 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: 9926 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 9926 is expected to become profitable in the next 3 years.

Revenue vs Market: 9926's revenue (32.8% per year) is forecast to grow faster than the Hong Kong market (7.5% per year).

High Growth Revenue: 9926's revenue (32.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 9926's Return on Equity is forecast to be high in 3 years time (22.4%)

Akeso Future Growth

Future criteria checks 6/6

Key information

Recent future growth updates

Akeso, Inc. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Results: Akeso, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

The Akeso, Inc. (HKG:9926) Half-Yearly Results Are Out And Analysts Have Published New Forecasts

Forecast to breakeven in 2023

Forecast to breakeven in 2023

No longer forecast to breakeven

Recent updates

Akeso, Inc. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

First half 2024 earnings released: CN¥0.28 loss per share (vs CN¥3.02 profit in 1H 2023)

Akeso, Inc. to Report Q2, 2024 Results on Aug 28, 2024

Akeso, Inc. Announces Ivonescimab (Pd-1/Vegf) Received Priority Review from China's Nmpa for First-Line Treatment of Pd-L1 Positive Nsclc

Akeso, Inc. Announces That the First Patient Enrolled in the US Phase 2 Combination Therapy of it's Ligufalimab with Azacitidine for Myelodysplastic Syndrome

Akeso's Sbla for Ivonescimab in 1L Treatment of Pd-L1 Positive Nsclc Accepted by NMPA

Akeso, Inc. Announces Appointment of Bing C. Wang as Chief Financial Officer

New major risk - Share price stability

Akeso, Inc. Announces Change of Directors

Akeso, Inc.'s (HKG:9926) CEO Compensation Is Looking A Bit Stretched At The Moment

Little Excitement Around Akeso, Inc.'s (HKG:9926) Revenues As Shares Take 25% Pounding

Akeso, Inc., Annual General Meeting, Jun 30, 2024

Akeso, Inc. Announces Phase III Clinical Trial, Harmoni-2 or AK112-303 Met Its Primary Endpoint of Progression-Free Survival

Are Investors Undervaluing Akeso, Inc. (HKG:9926) By 43%?

New minor risk - Share price stability

Akeso, Inc. Receives NMPA's Marketing Approval in China for Ivonescimab Injection

Investor sentiment deteriorates as stock falls 24%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price

National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer

New minor risk - Shareholder dilution

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

We Think Akeso's (HKG:9926) Robust Earnings Are Conservative

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Results: Akeso, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 15%

Akeso, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC

Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI

Akeso, Inc. Announces Innovative Clinical Development Roadmap

Akeso, Inc. Announces National Medical Products Administration Accepts the Supplemental New Drug Application for Kai Tan Ni (Cadonilimab, PD-1/CTLA-4) in Combination with Chemotherapy as First-Line Treatment for Gastric Cancer

Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price

Akeso, Inc. Publishes Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-nave Acute Myeloid Leukemia at ASH 2023

Akeso Publishes Results from Three Investigator-Initiated Trials

Founder recently sold HK$96m worth of stock

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso, Inc. Announces AK104-303, A Phase III Trial of Cadonilimab Reached Progression-Free-Survival Primary Endpoint At Interim Analysis for First Line Treatment of Cervical Cancer

An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 34% Undervalued

Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)

Co-Founder recently sold HK$4.4m worth of stock

Investor sentiment improves as stock rises 17%

Akeso Announces Results of Phase Ib Clinical Trial for PD-1/VEGF Bispecific Antibody

Akeso Announces the Publication of the Phase 1a/1b First-In-Human Study

Akeso, Inc. Announces Clinical Results from Cadonilimab in Patients with Advanced Solid Tumours (COMPASSION-03/AK104-201)

Is Akeso (HKG:9926) Using Too Much Debt?

Akeso, Inc. Announces FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes

The Akeso, Inc. (HKG:9926) Half-Yearly Results Are Out And Analysts Have Published New Forecasts

First half 2023 earnings released: EPS: CN¥3.02 (vs CN¥0.77 loss in 1H 2022)

New major risk - Revenue and earnings growth

Akeso Inc. Announces Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-Line PD-L1 Positive Advanced NSCLC

Akeso, Inc. Announces the National Medical Products Administration Accepts the New Drug Application for the Ebdarokimab Injection (IL-12/IL-23 Monoclonal Antibody, AK101)

Akeso Inc. Announces First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-Line Treatment of Squamous NSCLC

Akeso, Inc. to Report First Half, 2023 Results on Aug 29, 2023

New minor risk - Share price stability

Is Akeso, Inc. (HKG:9926) Trading At A 40% Discount?

Akeso, Inc., Annual General Meeting, Jun 28, 2023

NMPA Accepts Akeso's Ebronucimab (PCSK9 ) Marketing Application in Two Cardiovascular Indications

There's Reason For Concern Over Akeso, Inc.'s (HKG:9926) Price

Health Check: How Prudently Does Akeso (HKG:9926) Use Debt?

Growth Investors: Industry Analysts Just Upgraded Their Akeso, Inc. (HKG:9926) Revenue Forecasts By 18%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Forecast to breakeven in 2023

An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 49% Undervalued

Akeso, Inc. Announces China NMPA Approved Anniko (Penpulimab) for First-Line Treatment of Locally Advanced or Metastatic Squamous NSCLC

Now 24% undervalued

Akeso Inc. Announces JITC publication of Akeso's Ligufalimab(CD47 monoclonal antibody) Mechanism Shows Promising Antitumor Efficacy and Favorable Safety Profile